Compare VIK & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIK | TAK |
|---|---|---|
| Founded | 1997 | 1781 |
| Country | Bermuda | Japan |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6B | 55.5B |
| IPO Year | 2023 | 2007 |
| Metric | VIK | TAK |
|---|---|---|
| Price | $92.08 | $18.23 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $84.14 | N/A |
| AVG Volume (30 Days) | 3.1M | ★ 3.5M |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.41 | $0.16 |
| Revenue Next Year | $14.16 | $1.22 |
| P/E Ratio | ★ $37.68 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.37 | $12.99 |
| 52 Week High | $110.09 | $18.90 |
| Indicator | VIK | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 36.96 | 64.71 |
| Support Level | $68.14 | $17.40 |
| Resistance Level | $92.85 | $18.74 |
| Average True Range (ATR) | 3.97 | 0.21 |
| MACD | -1.70 | 0.07 |
| Stochastic Oscillator | 22.27 | 85.45 |
Viking Holdings Ltd is a travel company, with a fleet of 92 small ships, which view as floating hotels. It offers travel experiences on all seven continents in all three categories of the cruise industry river, ocean, and expedition cruising. The Group defines its products based on the type of cruise offering and language of the cruise service. The River segment provides river cruises outside the United States to English-speaking passengers. The Ocean segment offers ocean cruises to English-speaking passengers. Other include operating segments that are not individually reportable, consisting of expedition cruises for English-speaking passengers (Expedition), Mississippi River cruises for English-speaking passengers, and Viking China, which includes cruises for Mandarin.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.